LUCD Lucid Diagnostics (LUCD) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001799011
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
82
13F, latest reported quarter
What the filings say about LUCD
Insiders, 180 days
+$245.0K net bought
1 buyer
Lucid Diagnostics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Lucid Diagnostics Inc. insiders bought a net $245.0K of stock across 15 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Aug 20, 2025.
- -22.0% median (-16.9% mean) 90-day return after 4 previous buys.
- The trade is 23.7% of the 1,033,443 shares held after it.
- No other insider bought within 30 days.
- 82 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Matheis Dennis bought about $245.0K of LUCD on May 20, 2026, the largest insider purchase at the company since 2021; 82 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on May 22, 2025.
- -22.6% median (-23.1% mean) 90-day return after 3 previous buys.
- The trade is 15.0% of the 665,443 shares held after it.
- No other insider bought within 30 days.
- 82 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Matheis Dennis bought about $102.0K of LUCD on Aug 20, 2025; 82 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on May 21, 2025.
- -23.4% median (-23.4% mean) 90-day return after 2 previous buys.
- The trade is 5.9% of the 565,443 shares held after it.
- No other insider bought within 30 days.
- 82 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Matheis Dennis bought about $43.8K of LUCD on May 22, 2025; 82 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 20, 2025.
- The trade is 24.4% of the 532,225 shares held after it.
- No other insider bought within 30 days.
- 82 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Matheis Dennis bought about $171.2K of LUCD on May 21, 2025; 82 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 46.5% of the 402,541 shares held after it.
- No other insider bought within 30 days.
- 82 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Matheis Dennis bought about $243.2K of LUCD on May 20, 2025, the largest insider purchase at the company since 2021; 82 funds added in the latest 13F quarter.15 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$245.0K over 180 days
more than 79% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
82 funds bought in last quarter
more than 58% of Medical Devices
Revenue
+8.3% year over year
below 54% of Medical Devices
Margin
-1232.7% net margin
below 98% of Medical Devices
Buybacks
no share repurchases reported
Short interest
9.6% of the float short (float per yahoo 2026-10-26) · 10.3 days to cover · settled 2026-09-30
more than 76% of Medical Devices
The situation: each line is one rule over one dataset
2 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch LUCD
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-66.3%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns LUCD: institutional holders (13F)
13F holdings, latest reported quarter
8,856,844 sh
$9.5M
8,373,117 sh
$9.0M
6,556,344 sh
$7.0M
6,000,000 sh
$6.4M
4,000,000 sh
$4.3M
Congress trades in LUCD
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
LUCD planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
LUCD mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
U.S. Small Cap Equity Fund
$148.6K position · as of 2026-06-30
0.1%
iShares Micro-Cap ETF
$532.8K position · as of 2026-06-30
0.0%
U.S. Small Cap Equity Fund
$162.6K position · as of 2026-07-31
0.0%
1290 VT Micro Cap Portfolio
$35.8K position · as of 2026-06-30
0.0%
iShares Russell 2000 Growth ETF
$1.5M position · as of 2026-06-30
0.0%
PD Small-Cap Growth Index Portfolio
$14.5K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
5
Not applicable
2 active
What changed recently
Lucid Registry Study
2026-09-23 · Completion moved 2024-06-01 → 2027-12-31
,
Lucid Registry Study
2026-09-23 · Unknown → Recruiting
,
Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD fo
2026-09-22 · Completion moved 2023-12 → 2027-06-01
Not applicable
Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD fo
2026-09-22 · Unknown → Active Not Recruiting
Not applicable
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $245.0K bought by insiders over 180 days, 82 funds added last quarter. Each figure is a federal filing, dated the day it went public.
LUCD financials
Revenue growth
+8.3%
XBRL, annual
Net margin
-1232.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$5.4M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM LUCD
| FY Dec 2025 | $4.7M |
| FY Dec 2024 | $4.3M |
| FY Dec 2023 | $2.4M |
| FY Dec 2022 | $377.0K |
| FY Dec 2021 | n/a |
| Jun 2026 | $1.5M |
| Mar 2026 | $1.3M |
| Dec 2025 | $1.5M |
| Sep 2025 | $1.2M |
| Jun 2025 | $1.2M |
| Mar 2025 | $828.0K |
| Dec 2024 | $1.2M |
| Sep 2024 | $1.2M |
At each fiscal year end
Single quarter
Net margin, TTM
-959.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM LUCD
| FY Dec 2025 | -1,233% |
| FY Dec 2024 | -1,048% |
| FY Dec 2023 | -2,169% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -792.9% |
| Mar 2026 | -1,107% |
| Dec 2025 | -1,082% |
| Sep 2025 | -858.5% |
| Jun 2025 | -381.7% |
| Mar 2025 | -3,250% |
| Dec 2024 | -964.2% |
| Sep 2024 | -1,056% |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM LUCD
| FY Dec 2025 | n/a |
| FY Dec 2024 | -$47.2M |
| FY Dec 2023 | -$35.9M |
| FY Dec 2022 | -$32.9M |
| FY Dec 2021 | -$18.5M |
| Jun 2026 | -$11.3M |
| Mar 2026 | -$12.3M |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | -$10.6M |
| Mar 2025 | -$12.6M |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
2.22x
long-term debt only, 2021-09-30 (57 months older than the period end); equity 2026-06-30
Debt to equity LUCD
| FY Dec 2025 | 2.22x |
| FY Dec 2024 | 4.50x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 1.05x |
| FY Dec 2021 | 0.44x |
| Jun 2026 | 2.22x |
| Mar 2026 | 6.07x |
| Dec 2025 | 2.22x |
| Sep 2025 | 0.94x |
| Jun 2025 | 3.09x |
| Mar 2025 | n/a |
| Dec 2024 | 4.50x |
| Sep 2024 | 3.83x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-1.93x
TTM operating cash flow over long-term debt only, 2021-09-30 (57 months older than the period end)
Cash flow to debt LUCD
| FY Dec 2025 | -1.91x |
| FY Dec 2024 | -1.82x |
| FY Dec 2023 | -1.35x |
| FY Dec 2022 | -1.22x |
| FY Dec 2021 | -0.73x |
| Jun 2026 | -1.93x |
| Mar 2026 | -1.90x |
| Dec 2025 | -1.91x |
| Sep 2025 | -1.80x |
| Jun 2025 | -1.77x |
| Mar 2025 | -1.81x |
| Dec 2024 | -1.82x |
| Sep 2024 | -1.82x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-556.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity LUCD
| FY Dec 2025 | -710.6% |
| FY Dec 2024 | -2,956% |
| FY Dec 2023 | -508.0% |
| FY Dec 2022 | -144.4% |
| FY Dec 2021 | -136.2% |
| Jun 2026 | -556.3% |
| Mar 2026 | n/a |
| Dec 2025 | -710.6% |
| Sep 2025 | -331.2% |
| Jun 2025 | -463.6% |
| Mar 2025 | -1,897% |
| Dec 2024 | -2,956% |
| Sep 2024 | -1,008% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-134.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets LUCD
| FY Dec 2025 | -163.0% |
| FY Dec 2024 | -157.0% |
| FY Dec 2023 | -176.2% |
| FY Dec 2022 | -122.8% |
| FY Dec 2021 | -91.8% |
| Jun 2026 | -134.7% |
| Mar 2026 | -134.6% |
| Dec 2025 | -163.0% |
| Sep 2025 | -140.6% |
| Jun 2025 | -151.8% |
| Mar 2025 | -190.7% |
| Dec 2024 | -157.0% |
| Sep 2024 | -160.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital LUCD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-490.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed LUCD
| FY Dec 2025 | -521.1% |
| FY Dec 2024 | -1,813% |
| FY Dec 2023 | -441.3% |
| FY Dec 2022 | -142.7% |
| FY Dec 2021 | -104.1% |
| Jun 2026 | -490.3% |
| Mar 2026 | -10,699% |
| Dec 2025 | -521.1% |
| Sep 2025 | -271.7% |
| Jun 2025 | -350.2% |
| Mar 2025 | -1,151% |
| Dec 2024 | -1,813% |
| Sep 2024 | -793.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing LUCD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$60.5M
market value at close 2026-10-23 on 2026-08-10 shares, plus long-term debt only, 2021-09-30 (57 months older than the period end), minus cash 2025-09-30
Enterprise value LUCD
| FY Dec 2025 | $126.8M |
| FY Dec 2024 | $56.8M |
| FY Dec 2023 | $68.4M |
| FY Dec 2022 | $55.0M |
| FY Dec 2021 | $168.3M |
| Jun 2026 | $194.2M |
| Mar 2026 | $180.4M |
| Dec 2025 | $126.8M |
| Sep 2025 | $115.8M |
| Jun 2025 | $117.8M |
| Mar 2025 | $134.6M |
| Dec 2024 | $56.8M |
| Sep 2024 | $55.0M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield LUCD
| FY Dec 2025 | n/a |
| FY Dec 2024 | -86.1% |
| FY Dec 2023 | -57.0% |
| FY Dec 2022 | -61.8% |
| FY Dec 2021 | -9.4% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -86.1% |
| Sep 2024 | -104.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing LUCD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $4.7M | $4.3M | $2.4M | $377.0K |
| Gross profit | n/a | n/a | n/a | $377.0K |
| Operating income | -$49.6M | -$46.1M | -$48.5M | -$56.3M |
| Net income | -$58.0M | -$45.5M | -$52.7M | -$56.2M |
| EPS (diluted) | n/a | -1.05 | -1.26 | -1.55 |
| Operating cash flow | -$46.5M | -$44.1M | -$32.8M | -$29.7M |
| Cash | n/a | $22.4M | $18.9M | $22.5M |
SEC XBRL, fiscal years, as known on 2026-10-27
LUCD Stock Sonar score 6/7 axes
Find similar shapesCompareLUCD ranks highest on insider conviction (65th percentile) and institutional and government (58th), and lowest on profitability (6th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
LUCD filings, in plain words
Are Lucid Diagnostics insiders buying or selling LUCD?
In the 180 days to 2026-10-27, Lucid Diagnostics insiders were net buyers, a net $245.0K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-27, Lucid Diagnostics insiders were net buyers of LUCD, a net $245.0K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
